Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

83 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
A phase II trial of nivolumab followed by ipilimumab and nivolumab in advanced non-clear-cell renal cell carcinoma.
Conduit C, Davis ID, Goh JC, Kichenadasse G, Gurney H, Harris CA, Pook D, Krieger L, Parnis F, Underhill C, Adams D, Roncolato F, Joshua A, Ferguson T, Prithviraj P, Morris M, Harrison M, Begbie S, Hovey E, George M, Liow EC, Link EK, McJannett M, Gedye C; Australian and New Zealand Urogenital and Prostate Cancer Trials Group (ANZUP); UNISoN Investigators. Conduit C, et al. Among authors: gedye c. BJU Int. 2024 Feb;133 Suppl 3:57-67. doi: 10.1111/bju.16190. Epub 2023 Nov 20. BJU Int. 2024. PMID: 37986556 Clinical Trial.
Immunotherapy of advanced or metastatic melanoma.
Cebon J, Gedye C, John T, Davis ID. Cebon J, et al. Among authors: gedye c. Clin Adv Hematol Oncol. 2007 Dec;5(12):994-1006. Clin Adv Hematol Oncol. 2007. PMID: 18277962 Review.
Cancer stem cells in urologic cancers.
Gedye C, Davidson AJ, Elmes MR, Cebon J, Bolton D, Davis ID. Gedye C, et al. Urol Oncol. 2010 Nov-Dec;28(6):585-90. doi: 10.1016/j.urolonc.2009.06.010. Epub 2009 Nov 7. Urol Oncol. 2010. PMID: 19897386 Review.
Human perforin mutations and susceptibility to multiple primary cancers.
Trapani JA, Thia KY, Andrews M, Davis ID, Gedye C, Parente P, Svobodova S, Chia J, Browne K, Campbell IG, Phillips WA, Voskoboinik I, Cebon JS. Trapani JA, et al. Among authors: gedye c. Oncoimmunology. 2013 Apr 1;2(4):e24185. doi: 10.4161/onci.24185. Oncoimmunology. 2013. PMID: 23734337 Free PMC article.
New treatments for metastatic melanoma.
Gedye C, Hogg D, Butler M, Joshua AM. Gedye C, et al. CMAJ. 2014 Jul 8;186(10):754-60. doi: 10.1503/cmaj.130989. Epub 2014 Feb 18. CMAJ. 2014. PMID: 24549129 Free PMC article. Review. No abstract available.
Results of a Prospective Phase 2 Pilot Trial of 177Lu-PSMA-617 Therapy for Metastatic Castration-Resistant Prostate Cancer Including Imaging Predictors of Treatment Response and Patterns of Progression.
Emmett L, Crumbaker M, Ho B, Willowson K, Eu P, Ratnayake L, Epstein R, Blanksby A, Horvath L, Guminski A, Mahon K, Gedye C, Yin C, Stricker P, Joshua AM. Emmett L, et al. Among authors: gedye c. Clin Genitourin Cancer. 2019 Feb;17(1):15-22. doi: 10.1016/j.clgc.2018.09.014. Epub 2018 Sep 27. Clin Genitourin Cancer. 2019. PMID: 30425003 Clinical Trial.
[177Lu]Lu-PSMA-617 versus cabazitaxel in patients with metastatic castration-resistant prostate cancer (TheraP): a randomised, open-label, phase 2 trial.
Hofman MS, Emmett L, Sandhu S, Iravani A, Joshua AM, Goh JC, Pattison DA, Tan TH, Kirkwood ID, Ng S, Francis RJ, Gedye C, Rutherford NK, Weickhardt A, Scott AM, Lee ST, Kwan EM, Azad AA, Ramdave S, Redfern AD, Macdonald W, Guminski A, Hsiao E, Chua W, Lin P, Zhang AY, McJannett MM, Stockler MR, Violet JA, Williams SG, Martin AJ, Davis ID; TheraP Trial Investigators and the Australian and New Zealand Urogenital and Prostate Cancer Trials Group. Hofman MS, et al. Among authors: gedye c. Lancet. 2021 Feb 27;397(10276):797-804. doi: 10.1016/S0140-6736(21)00237-3. Epub 2021 Feb 11. Lancet. 2021. PMID: 33581798 Clinical Trial.
83 results